We also anticipate that this will further enable the exploration of the use of hMG transplantation as a therapeutic modality for various diseases [7, 32] Particularly in combination with the newly developed CSF1R inhibitor-resistant human CSF1R variant [8]) and the broader advances the scientific community is making on the use of transplantation models for the treatment of neurological disorders such as epilepsy or Parkinson disease (Svendsen 2024 Nat Med), stem cell-based therapies using microglia may hold a place in disease treatment in the not-too distant future. The gene discussed is CSF1R; the disease is Parkinson disease.